At a glance
ClinicalIndex Comparison RecordN/ACompleted· 8 enrolled
Drug / intervention
App randomizing dosing regimendevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Improving the Effect of Dimethyl Fumarate and Diroximel Fumarate (DRF) for Patients With Multiple Sclerosis by Chronobiology
In Brief
A clinical study evaluating App randomizing dosing regimen for Multiple Sclerosis. Completed, enrolled 8 participants across 1 site.
Detailed Summary
A trial for evaluating the ability to improve the effect of dimethyl fumarate in patients with Multiple Sclerosis (MS) by chronobiology A controlled-randomization dosing regimen administered to patients with MS and provided by a designated app. The treatment limitations of time interval is pre-defined according to approved therapeutic windows.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesIsrael
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartMay 2022
Primary CompletionJun 2023
Study CompletionJun 2023
First PostedApr 2024
TodayJul 2026
First PostedApr 25, 2024
Enrollment StartMay 8, 2022
Primary CompletionJun 1, 2023
Study CompletionJun 2, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.2 years ago
Interventions
App randomizing dosing regimendevice
patients will receive their dimethyl fumarate treatment and the dose and time of administration will be determined using a designated app.